Transitional cell carcinoma+1
Not yet recruitingStudy of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma
Study of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma
- Disease:Transitional cell carcinomaTransitional cell carcinoma metastatic
- Substances:Enfortumab VedotinIvonescimab+1
Spain- Participants:18–64 years · 65+ years
- Substances:Enfortumab Vedotin
